Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Chronic Migraine Patients: COMPEL Analysis by Treatment Cycle

被引：0
作者：
Brin, Mitchell F. [1 ,2 ]
Winner, Paul [3 ]
Blumenfeld, Andrew M. [4 ]
Eross, Eric J. [5 ]
Orejudos, Amelia [1 ]
Adams, Aubrey Manack [1 ]
机构：
[1] Allergan Plc, Irvine, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
[3] Premiere Res Inst Palm Beach Neurol, Palm Beach Headache Ctr, W Palm Beach, FL USA
[4] Headache Ctr Southern Calif, Neurol Ctr, Carslbad, CA USA
[5] CORE Inst, Scottsdale, AZ USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P4.123
引用
收藏
页数：3
相关论文
共 50 条
[21]   Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting [J].
Kollewe, Katja ;
Escher, Claus M. ;
Wulff, Dirk U. ;
Fathi, Davood ;
Paracka, Lejla ;
Mohammadi, Bahram ;
Karst, Matthias ;
Dressler, Dirk .
JOURNAL OF NEURAL TRANSMISSION, 2016, 123 (05) :533-540
[22]   Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL [J].
Blumenfeld, Andrew ;
Stark, Richard ;
Adams, Aubrey Manack ;
Orejudos, Amelia ;
Aurora, Sheena .
NEUROLOGY, 2017, 88
[23]   Efficacy and Safety of OnabotulinumtoxinA in an Open-Label Study for the Prophylactic Treatment of Chronic Migraine in Adult Patients: COMPEL [J].
Blumenfeld, Andrew ;
Stark, Richard ;
Adams, Aubrey Manack ;
Orejudos, Amelia ;
Aurora, Sheena .
NEUROLOGY, 2017, 88
[24]   Rationale for Study and Design of COMPEL: An Open-Label, Multicenter Study of the Long-Term Efficacy, Safety, and Tolerability of OnabotulinumtoxinA for Headache Prophylaxis in Adults with Chronic Migraine [J].
Blumenfeld, A. M. ;
Aurora, S. K. ;
Laranjo, K. ;
Varon, S. F. ;
Papapetropoulos, S. .
HEADACHE, 2012, 52 (05) :881-881
[25]   OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse [J].
Guerzoni, Simona ;
Cainazzo, Maria Michela ;
Pini, Luigi Alberto .
JOURNAL OF HEADACHE AND PAIN, 2015, 16
[26]   Efficacy and safety of onabotulinumtoxinA for the prophylaxis of headaches in adult chronic migraine patients: an interim analysis of the prospective, long-term, multicenter, open-label study, COMPEL [J].
Blumenfeld, A. ;
Stark, R. ;
Reppine, A. ;
Halstead, M. ;
Holdbrook, F. ;
Adams, A. Manack ;
Aurora, S. .
JOURNAL OF PAIN, 2015, 16 (04) :S92-S92
[27]   Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine [J].
Andrew M. Blumenfeld ;
Sheena K. Aurora ;
Karen Laranjo ;
Spyros Papapetropoulos .
BMC Neurology, 15
[28]   Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine [J].
Blumenfeld, Andrew M. ;
Aurora, Sheena K. ;
Laranjo, Karen ;
Papapetropoulos, Spyros .
BMC NEUROLOGY, 2015, 15
[29]   Long-term experience with onabotulinumtoxina in the treatment of chronic migraine: lessons after one year [J].
Pascual, J. ;
Ramon, C. ;
Larrosa, D. ;
Riesco, N. ;
Alvarez, R. ;
Cernuda-Morollon, E. .
CEPHALALGIA, 2015, 35 :54-54
[30]   OnabotulinumtoxinA for Chronic Migraine: Safety and Tolerability of the Effective Treatment Paradigm in the PREEMPT Clinical Program [J].
Aurora, S. K. ;
Dodick, D. W. ;
Blumenfeld, A. ;
DeGryse, R. E. ;
Turkel, C. C. .
HEADACHE, 2010, 50 :S14-S15
12345